Antihypertensive and lipid‐lowering drugs usage after primary stroke in a large representative sample of the French population

2022 ◽  
Author(s):  
Julia Perrier ◽  
Valérie Olié ◽  
Amélie Gabet ◽  
Christophe Tzourio ◽  
Julien Bezin
Keyword(s):  
Representative Sample ◽  
Lipid Lowering ◽  
French Population ◽  
Lipid Lowering Drugs ◽  
Large Representative

Sharp rise in vaccine hesitancy in a large and representative sample of the French population: reasons for vaccine hesitancy.

2020 ◽  
Author(s):  
Anne-Sophie Hacquin ◽  
Sacha Altay ◽  
Emma de Araujo ◽  
Coralie Chevallier ◽  
Hugo Mercier
Keyword(s):  
At Risk ◽  
Educational Level ◽  
Representative Sample ◽  
Vaccine Hesitancy ◽  
The Political ◽  
French Population ◽  
Sharp Rise ◽  
Vaccine Refusal ◽  
French People ◽  
Nationally Representative

A safe and effective COVID-19 vaccine is our only hope to decisively stop the spread of the SARS-CoV-2. But a vaccine will only be fully effective if a significant share of the population agrees to get it. Five consecutive surveys of a large, nationally representative sample (N = 1000 for each wave) surveyed attitudes towards a future COVID-19 vaccine in France from May 2020 to October 2020. We found that COVID-19 vaccine refusal has steadily increased, reaching an all-time high with only 23% of participants willing to probably or certainly take a future COVID-19 vaccine in September 2020. Vaccine hesitant individuals are more likely to be women, young, less educated, to vote at the political extremes, to be dissatisfied with the government’s response to the COVID-19 crisis, and to feel less at risk of COVID-19. The reasons why French people would refuse to take the COVID-19 vaccine are similar to those offered for other vaccines, and these reasons are strikingly stable across gender, age and educational level. Finally, most French people declare they would not take the vaccine as soon as possible but would instead rather wait or not take it at all.

The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings

2018 ◽  
Vol 16 (4) ◽  
pp. 368-375 ◽  
Author(s):  
Abdullah Shehab ◽  
Khalid Al-Rasadi ◽  
Mohamed Arafah ◽  
Ali T. Al-Hinai ◽  
Wael Al Mahmeed ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Lipid Lowering ◽  
Lipid Lowering Drugs
Sign in / Sign up

Export Citation Format

Share Document